Posted by Michael Wonder on 29 Oct 2020
NICE announces start of review of nusinersen Managed Access Agreement
29 October 2020 - NICE has today announced that it has begun the process to review data collected as part of the Managed Access Agreement for nusinersen (Spinraza, Biogen) for treating the rare genetic disorder spinal muscular atrophy.
The review, involving Biogen, patient groups, clinicians, SMA REACH UK and NHS England and NHS Improvement, will assess whether new evidence has become available to support a change in the MAA treatment eligibility criteria.
Specifically, it will consider whether people with type III spinal muscular atrophy who are unable to walk can benefit from the treatment and therefore should be included in the Managed Access Agreement.
